A number of firms have modified their ratings and price targets on shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) recently:
- 11/12/2026 – Madrigal Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright.
- 11/7/2026 – Madrigal Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
- 11/4/2026 – Madrigal Pharmaceuticals is now covered by HC Wainwright. They set a “strong-buy” rating on the stock.
- 11/4/2026 – Madrigal Pharmaceuticals had its price target raised by Canaccord Genuity Group from $612.00 to $633.00. They now have a “buy” rating on the stock.
- 11/4/2026 – Madrigal Pharmaceuticals had its “buy” rating reaffirmed by Truist Financial. They now have a $743.00 price target on the stock, up from $709.00.
- 11/3/2026 – Madrigal Pharmaceuticals had its price target raised by Citigroup from $725.00 to $760.00. They now have a “buy” rating on the stock.
- 10/15/2026 – Madrigal Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 10/14/2026 – Madrigal Pharmaceuticals had its “buy” rating reaffirmed by UBS Group. They now have a $735.00 price target on the stock.
- 9/24/2026 – Madrigal Pharmaceuticals is now covered by The Goldman Sachs Group. They set a “buy” rating and a $704.00 price target on the stock.
- 9/24/2026 – Madrigal Pharmaceuticals is now covered by The Goldman Sachs Group. They set a “buy” rating and a $704.00 price target on the stock.
- 9/23/2026 – Madrigal Pharmaceuticals is now covered by Citigroup. They set a “buy” rating and a $725.00 price target on the stock.
- 9/23/2026 – Madrigal Pharmaceuticals is now covered by Citigroup. They set a “buy” rating and a $725.00 price target on the stock.
Madrigal Pharmaceuticals Stock Down 0.5%
MDGL stock opened at $421.99 on Wednesday. Madrigal Pharmaceuticals, Inc. has a twelve month low of $353.54 and a twelve month high of $615.00. The company has a quick ratio of 2.78, a current ratio of 3.05 and a debt-to-equity ratio of 0.54. The stock has a market cap of $9.80 billion, a P/E ratio of -70.57 and a beta of -0.98. The business’s 50-day moving average price is $471.14 and its 200-day moving average price is $495.06.
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.09) by $2.92. The company had revenue of $431.27 million during the quarter, compared to the consensus estimate of $404.17 million. Madrigal Pharmaceuticals had a negative return on equity of 27.08% and a negative net margin of 10.89%. During the same period in the previous year, the company posted ($5.08) EPS. On average, equities research analysts forecast that Madrigal Pharmaceuticals, Inc. will post -2.08 EPS for the current year.
Insider Buying and Selling at Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania. Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.
Read More
- Five stocks we like better than Madrigal Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Madrigal Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
